Other News

Biosense Webster, Inc. Announces Catheter Ablation May Be up to 10 Times More Effective Than Standard Drug Therapy Alone at Delaying Progression of Atrial Fibrillation

PARIS–(BUSINESS WIRE)–Results from The Atrial Fibrillation Progression Trial (ATTEST), were presented on August 31st at the ESC* Congress 2019 in Paris, France. ATTEST is the first randomised controlled trial to directly compare the effectiveness of ablation using radiofrequency (RF) catheters versus standard antiarrhythmic drugs (AAD) in delaying atrial fibrillation (AF) progression. The […]

Impella® SmartAssist Platform Launches at ESC, Designed to Further Improve Patient Outcomes

The new Impella CP heart pump features a fiber optic sensor, optimally positioned to measure the placement signal in the aorta, identify pump placement and enable repositioning without the use of imaging. (Graphic: Abiomed) PARIS–(BUSINESS WIRE)–Abiomed (NASDAQ: ABMD) announces today that the Impella CP® with SmartAssist technology, which is designed to improve patient […]

Shockwave Receives FDA Breakthrough Device Designation for the Coronary IVL System

SANTA CLARA, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced that the company has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Shockwave […]

Quantum Genomics Announces Positive FDA Feedback on Phase III Program Design of Firibastat in Resistant Arterial Hypertension

PARIS and NEW YORK, Sept. 02, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant arterial hypertension and heart failure, today announced that it met a new milestone of […]

MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019

Durability of Mavacamten’s Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes in Key Biomarkers Maintained, Indicative of Potential Improvements in Cardiac Function and Favorable Impact on Long-Term Disease Burden PARIS and SOUTH SAN FRANCISCO, Calif., Aug. 31, 2019 (GLOBE NEWSWIRE) […]

Ablative Solutions Announces Positive 12-Month Results from Study Evaluating Company’s Novel Therapy for Uncontrolled Hypertension

SAN JOSE, Calif. and PARIS, Sept. 3, 2019 /PRNewswire/ — Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced 12-month results from the Peregrine Post-Market Clinical Trial, which were presented today during a symposium at the 2019 European Society of Cardiology (ESC) Congress in Paris. The Peregrine Post-Market Study is […]

Beacon® Tip Catheters Available in Europe Again

LIMERICK, Ireland–(BUSINESS WIRE)–Cook Medical is pleased to announce that Beacon® Tip Catheters are once again available to physicians in Europe. As of September 2019, the catheters are available in the UK, Ireland, Norway, Sweden, Finland, Denmark, Germany, Poland, the Netherlands, Luxembourg, Belgium, France, Switzerland, Austria, Hungary, Spain and Italy. Cook is […]

First-in-Human Telerobotic Coronary Intervention Procedures Published in The Lancet Journal, EClinicalMedicine

Renowned medical journal publishes the successful clinical results of remote PCI procedures using CorPath® GRX Robotic System technology WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that EClinicalMedicine, a clinical journal published by the nearly 200-year-old medical journal The Lancet, has […]

Detailed results from Phase III DAPA-HF trial showed FARXIGA significantly reduced both the incidence of cardiovascular death and the worsening of heart failure

DAPA-HF is the first outcomes trial with an SGLT2 inhibitor in patients with heart failure with reduced ejection fraction, with and without type 2 diabetes   September 1, 2019 – AstraZeneca today announced detailed results from the landmark Phase III DAPA-HF trial that showed FARXIGA (dapagliflozin) on top of standard […]